Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA

Background The prevalence of antibodies against M-type anti-phospholipase A2 receptor (PLA2R) was reported to be ~ 70–80% in early studies on idiopathic membranous nephropathy (iMN) cohorts from Western countries, China, and Korea, and ~ 50% in recent studies on two Japanese iMN cohorts. Methods We...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental nephrology 2019-04, Vol.23 (4), p.465-473
Main Authors: Kaga, Hajime, Komatsuda, Atsushi, Yamamoto, Soh, Kikuchi, Tadashi, Kamata, Mika, Sato, Akiko, Odaka, Masafumi, Yokota, Shin-ichi, Takahashi, Naoto, Wakui, Hideki
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies
Autoantibodies - blood
Case-Control Studies
Enzyme-linked immunosorbent assay
Enzyme-Linked Immunosorbent Assay - methods
Female
Glomerulonephritis, Membranous - blood
Glomerulonephritis, Membranous - etiology
Humans
Immunoglobulins
Japan
Male
Medicine
Medicine & Public Health
Membranous nephropathy
Middle Aged
Nephrology
Nephropathy
Nephrotic syndrome
Nephrotic Syndrome - blood
Original Article
Phospholipase A2
Proteinuria
Proteinuria - blood
Receptors, Phospholipase A2 - immunology
Serum Albumin - metabolism
Urology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The prevalence of antibodies against M-type anti-phospholipase A2 receptor (PLA2R) was reported to be ~ 70–80% in early studies on idiopathic membranous nephropathy (iMN) cohorts from Western countries, China, and Korea, and ~ 50% in recent studies on two Japanese iMN cohorts. Methods We developed an in-house enzyme-linked immunosorbent assay (ELISA) for the detection of anti-PLA2R antibodies, and examined sera from 217 patients with iMN, 22 patients with secondary MN (sMN), and 50 healthy individuals. All patients and healthy individuals were Japanese. The relationships between levels of anti-PLA2R antibodies and clinical parameters were analyzed. Serum samples were also tested using a standardized commercial ELISA (Euroimmun, Germany). Results In our ELISA, OD values greater than the mean + 3 standard deviation of healthy subjects were considered to be positive for anti-PLA2R antibodies. Of the patients with iMN, 33.6% (73/217) were positive, but all sMN patients were negative. Our ELISA and the Euroimmun ELISA had a high concordance (93.5%). The proportion of patients with nephrotic syndrome was significantly higher in anti-PLA2R antibody-positive patients than in antibody-negative patients (65.8 vs. 37.5%, P  
ISSN:1342-1751
1437-7799
DOI:10.1007/s10157-019-01712-x